DexCom (NASDAQ:DXCM) Downgraded by StockNews.com

StockNews.com lowered shares of DexCom (NASDAQ:DXCM) from a buy rating to a hold rating in a research note issued to investors on Tuesday morning.

Several other research analysts have also issued reports on DXCM. Raymond James upped their target price on shares of DexCom from $147.00 to $151.00 and gave the stock a strong-buy rating in a research report on Tuesday, January 23rd. Royal Bank of Canada started coverage on shares of DexCom in a research report on Tuesday, March 12th. They issued an outperform rating and a $165.00 target price for the company. UBS Group upped their price target on shares of DexCom from $153.00 to $163.00 and gave the company a buy rating in a research report on Wednesday, April 10th. Finally, Citigroup upped their price target on shares of DexCom from $148.00 to $161.00 and gave the company a buy rating in a research report on Wednesday, April 3rd. Three analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average price target of $141.40.

DexCom Stock Up 0.1 %

DXCM opened at $138.01 on Tuesday. DexCom has a one year low of $74.75 and a one year high of $142.00. The company has a fifty day moving average price of $130.98 and a 200-day moving average price of $118.02. The firm has a market capitalization of $54.66 billion, a P/E ratio of 105.35, a price-to-earnings-growth ratio of 2.30 and a beta of 1.20. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.84 and a quick ratio of 2.48.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.07. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The company had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.02 billion. During the same period in the previous year, the business earned $0.34 earnings per share. The firm’s quarterly revenue was up 26.9% compared to the same quarter last year. Equities research analysts expect that DexCom will post 1.76 earnings per share for the current fiscal year.

Insider Buying and Selling

In other DexCom news, EVP Matthew Vincent Dolan sold 1,990 shares of the company’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the sale, the executive vice president now owns 42,377 shares in the company, valued at $5,839,974.37. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other DexCom news, CEO Kevin R. Sayer sold 49,633 shares of the company’s stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $138.30, for a total value of $6,864,243.90. Following the sale, the chief executive officer now owns 283,893 shares in the company, valued at $39,262,401.90. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Matthew Vincent Dolan sold 1,990 shares of the company’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $137.81, for a total transaction of $274,241.90. Following the completion of the sale, the executive vice president now owns 42,377 shares in the company, valued at approximately $5,839,974.37. The disclosure for this sale can be found here. Insiders sold a total of 189,375 shares of company stock valued at $25,530,859 over the last three months. Corporate insiders own 0.41% of the company’s stock.

Institutional Investors Weigh In On DexCom

A number of institutional investors have recently made changes to their positions in DXCM. DSM Capital Partners LLC purchased a new stake in shares of DexCom during the fourth quarter valued at approximately $28,000. Valley National Advisers Inc. grew its holdings in shares of DexCom by 73.0% during the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after buying an additional 103 shares during the last quarter. Riverview Trust Co purchased a new stake in shares of DexCom during the first quarter valued at approximately $32,000. MV Capital Management Inc. grew its holdings in shares of DexCom by 99.3% during the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after buying an additional 138 shares during the last quarter. Finally, Smithfield Trust Co grew its holdings in shares of DexCom by 103.1% during the fourth quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock valued at $40,000 after buying an additional 165 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.